MET exon 14 alterations are oncogenic drivers of non-small-cell lung cancers (NSCLCs).
These alterations are associated with increased MET activity and preclinical sensitivity to …

108 Background: MET alterations leading to exon 14 skipping occur in~ 4% of lung
carcinomas, resulting in MET activation and sensitivity to MET inhibitors in vitro. Crizotinib …

Introduction MET proto-oncogene, receptor tyrosine kinase gene exon 14 skipping
(METex14) alterations represent a unique subset of oncogenic drivers in NSCLC …

Activation of the MET proto-oncogene (MET) highly sensitive to MET inhibition has recently
been described in NSCLC through two mechanisms: high-level amplification of the MNNG …

Introduction MET proto-oncogene, receptor tyrosine kinase gene (MET) exon 14 skipping is
a targetable alteration in lung cancer. Treatment with MET proto-oncogene, receptor tyrosine …

9062 Background: MET amplification (amp) has been reported in a subset of NSCLC with
the frequency varying depending on the definition used. Crizotinib, an ALK/ROS1/MET …

Introduction Tyrosine kinase inhibitors (TKIs) targeted to MET are undergoing clinical trials in
patients with solid tumors, but the precise mechanism of the antitumor activity of these drugs …

A number of small molecule tyrosine kinase inhibitors (TKIs) have now been approved for
the treatment of non-small cell lung cancers (NSCLC), including those targeted against …

Purpose: MET inhibitors can be effective therapies in patients with MET exon 14 (MET ex14)
mutant non–small cell lung cancer (NSCLC). However, long-term efficacy is limited by the …

Objectives Although dramatic responses to MET inhibitors have been reported in patients
with MET exon 14 (METex14) mutant non-small cell lung cancer (NSCLC), the impact of …